Clinical Trials Logo

Filter by:
NCT ID: NCT05372601 Completed - Clinical trials for Stress, Psychological

Prebiotics and Stress Reduction in Women

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

In modern life, many people state to experience stress. Women compared to men report more and higher levels of stress. Recent research found that supplementation of galactose-oligosaccharides (GOS) resulted in reduced anxiety levels in British female students with higher anxiety scores at baseline in self-reported trait anxiety. Moreover, supplementation of probiotics in germ-free rodents resulted in reduced levels of circulating corticosterone (cortisol in humans). These findings illustrate the potential of prebiotic supplementation, through the microbiota-gut-brain (MGB) axis, to improve mental health and wellbeing. The present study aims to study the effect of oligosaccharides on self-perceived stress.

NCT ID: NCT05365906 Completed - Clinical trials for Urinary Tract Infections

UTI Reference Standard: Delphi Method

ORACLE
Start date: April 12, 2022
Phase:
Study type: Observational

This study is set up by an international core group consisting of infectious disease specialists, geriatricians, urologists, microbiologists, emergency physicians and primary care physicians to develop a consensus-based research definition of urinary tract infections. The absence of such a reference standard leads to misclassification bias and heterogeneity between studies making progress in the field of UTI difficult, for example with much needed near patient diagnostic tests.

NCT ID: NCT05364242 Completed - Clinical trials for SARS-CoV-2 Infection

VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection

Start date: May 9, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.

NCT ID: NCT05363995 Completed - Insomnia Clinical Trials

Feasibility Trial i-Sleep & BioClock Intervention

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

Students often suffer from sleep problems and circadian rhythm disruptions which affect their mental health and daily functioning. The aim of this project is to develop, implement and evaluate an e-health intervention that targets the biological clock and improves the sleep patterns of university students in order to prevent the development or exacerbation of mental health problems. The investigators will assess the feasibility, usability and acceptability of the intervention in this pilot trial.

NCT ID: NCT05361499 Completed - Clinical trials for Streptococcus Pneumoniae Infection

A Controlled Human Pneumococcal Infection Model (PIM) Study

PIM
Start date: May 31, 2022
Phase: N/A
Study type: Interventional

Infection with Streptococcus pneumoniae (the pneumococcus) is the leading cause of pneumonia, bacterial meningitis and bacteraemia worldwide in the very young and the elderly. Although pneumococcal vaccines exist, they do not provide complete protection and new strategies to combat this pathogen are urgently needed. Asymptomatic infection of S. pneumoniae in the human nasopharynx precedes the development of pneumococcal disease. Previously, an Experimental Human Pneumococcal Carriage (EHPC) model has been developed at the Liverpool School of Tropical Medicine (LSTM). The current study entails to establish this model in healthy adults living in the Netherlands using the inoculation dose currently used at LSTM. Healthy adult participants (M/F) will be inoculated intranasally with strain BHN418, a penicillin sensitive serotype 6B strain of S. pneumoniae that was previously isolated from a healthy carrier. Following inoculation, participants will be monitored and blood and nasal samples will be collected over a period of 28 ± 3 days. Participants will receive a course of amoxicillin to eradicate infection on or shortly after the last visit at day 28 ± 3, unless S. pneumoniae is not detected on both day 14 and 28 ± 3 post-inoculation.

NCT ID: NCT05359549 Completed - Missing Teeth Clinical Trials

Dental Implant Treatment for Two Adjacent Teeth in the Maxillary Aesthetic Region: an Evaluation After 10 Years

2implants
Start date: October 6, 2022
Phase:
Study type: Observational [Patient Registry]

- Background Replacement of two missing adjacent teeth is considered a difficult treatment in implant dentistry and even more challenging if located in the anterior region due to aesthetic demands. As well peri-implant bone contour as soft tissue volume is compromised at start of the treatment and difficult to restore. The question is if this reconstruction will be stable in the longterm. Full-scale evaluation of adjacent implant placement with crown rehabilitation in the aesthetic region with a follow-up of at least 10 years is underreported in this field of implant dentistry. - Main research question The aim of this observational study was to analyze peri-implant bone changes, mucosa levels, aesthetic ratings and patient-reported satisfaction with the maxillary aesthetic region following implant placement with crown restoration after a 10-years follow-up period. - Design (including population, confounders/outcomes) The study design is an observational study of a group of patients with two missing adjacent teeth in the maxillary aesthetic region which was treated 10 years ago with dental implant placement and an implant-supported restorations. Outcomes: primary outcome is the change in marginal peri-implant bone level 10 years after placing the definitive restoration. Secondary outcome measures will be implant and restoration survival and changes in interproximal peri-implant mucosa, midfacial peri-implant mucosal level , aesthetic outcome assessed by means of an objective index and patients' satisfaction using a questionnaire. • Expected results Stable peri-implant bone levels, stable peri-implant soft tissue levels, high implant and restoration survival rate and satisfied patients.

NCT ID: NCT05354453 Completed - Healthy Clinical Trials

A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)

Start date: May 23, 2022
Phase: Phase 1
Study type: Interventional

This trial starts the clinical development of BI 1839100. Effects of single rising doses of BI 1389100 on safety, tolerability and pharmacokinetics will be assessed as basis for further development in patients with pulmonary fibrosis.

NCT ID: NCT05353595 Completed - Clinical trials for Muscle Protein Synthesis

The Effect of Mealworm Protein Ingestion on Muscle Protein Synthesis After Running Exercise in Humans

Centurion
Start date: June 3, 2022
Phase: N/A
Study type: Interventional

Rationale: Consumption of sufficient dietary protein is fundamental to skeletal muscle mass maintenance and overall health. Conventional animal-based protein sources such as meat, poultry, fish, eggs, and dairy are considered high-quality sources of dietary protein. However, the production of sufficient amounts of these conventional animal-based proteins to meet future global food demands will be challenging. Consequently, there is a great interest in more sustainable alternatives for these high-quality protein sources. Edible insects have recently been proposed as a high quality source of dietary protein. Insects are produced on a more viable and sustainable commercial scale and, as such, may contribute to ensuring global food security. Insect derived proteins represent a protein source that combines high quality with a (more) sustainable production. Though insect proteins have been suggested as a solution to secure future global dietary protein needs, there little data to support the bioavailability of insect derived proteins and their capacity to stimulate post-exercise muscle protein synthesis rates in vivo in humans. Objective: To assess the impact of ingesting mealworm derived protein on muscle protein synthesis rates during recovery from aerobic exercise in a group healthy men and women Study design: randomized, counter-balanced, cross-over design Study population: 20 healthy lean (BMI 18.5-30 kg/m2) young males and females (age: 18-35 y inclusive). Intervention: Subjects will perform running exercise and consume either 0.38 g per kg bodyweight mealworm protein or a non-caloric placebo. In addition, continuous intravenous tracer infusions will be applied, with plasma and muscle samples collected. Main study parameters/endpoints: The primary outcome will be post-exercise muscle protein synthesis rates following beverage ingestion.

NCT ID: NCT05353127 Completed - Colorectal Cancer Clinical Trials

Cardiopulmonary Exercise Test Data Averaging Methods and Preoperative Risk Assessment

Start date: April 12, 2022
Phase:
Study type: Observational

Cardiopulmonary exercise testing (CPET) is used for preoperative risk assessment in patients with colorectal cancer who need to undergo surgery. For presentation and interpretation purposes, CPET data are averaged by using a time- or breath-based average. It is uncertain to what extent differences in data averaging methods influence the numerical value of preoperative CPET-derived variables used for risk assessment. Therefore, the primary aim of this study is to investigate the influence of different CPET data averaging intervals on the numerical values of CPET-derived variables used for preoperative risk assessment in patients scheduled for elective colorectal cancer surgery. The secondary aim is to elucidate the impact of data-averaging intervals on classification of patients into a low- or high-risk category for postoperative complications based on known risk assessment thresholds.

NCT ID: NCT05352386 Completed - Clinical trials for Familial Hypercholesterolemia

Coronary and Heart Effects of Early Treatment in Familial Hypercholesterolemia

CHEETAH
Start date: March 7, 2022
Phase: N/A
Study type: Interventional

This study evaluates plaque burden and characteristics in early-treated FH patients compared to late-treated FH patients and healthy individuals.